Application of MicroRNA in Diagnosis and Treatment of Ovarian Cancer

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 May 14

PMID 24822185

Citations 31

Authors

Kouji Banno

Megumi Yanokura

Miho Iida

Masataka Adachi

Kanako Nakamura

Yuya Nogami

Kiyoko Umene

Kenta Masuda

Iori Kisu

Hiroyuki Nomura

Fumio Kataoka

Eiichiro Tominaga

Daisuke Aoki

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer has a poor prognosis because early detection is difficult and recurrent ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are high worldwide and new methods of diagnosis and therapy are needed. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression that are involved in carcinogenesis, metastasis, and invasion. Thus, miRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy. Many miRNAs have altered expression in ovarian cancer compared to normal ovarian tissues and these changes may be useful for diagnosis and treatment. For example, deficiencies of enzymes including Dicer and Drosha that are required for miRNA biogenesis may be adverse prognostic factors; miRNAs such as miR-214 and miR-31, which are involved in drug resistance, and the miR-200 family, which is implicated in metastasis, may serve as biomarkers; and transfection of downregulated miRNAs and inhibition of upregulated miRNAs may be effective for treatment of ovarian cancer. Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.

Citing Articles

A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy.

Bordoloi D, Bhojnagarwala P, Perales-Puchalt A, Kulkarni A, Zhu X, Liaw K JCI Insight. 2022; 7(22).

PMID: 36509287 PMC: 9746812. DOI: 10.1172/jci.insight.162553.

Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics.

Chen M, Lei N, Tian W, Li Y, Chang L Ther Adv Med Oncol. 2022; 14:17588359221118010.

PMID: 35983027 PMC: 9379276. DOI: 10.1177/17588359221118010.

Myricetin Suppresses Ovarian Cancer by Activating the p38/Sapla Signaling Pathway and Suppressing Intracellular Oxidative Stress.

Li Q, Tan Q, Ma Y, Gu Z, Chen S Front Oncol. 2022; 12:903394.

PMID: 35646711 PMC: 9130763. DOI: 10.3389/fonc.2022.903394.

Wnt antagonist as therapeutic targets in ovarian cancer.

Y K, Perumalsamy N, Warrier S, Perumalsamy L, Dharmarajan A Int J Biochem Cell Biol. 2022; 145:106191.

PMID: 35272015 PMC: 7616886. DOI: 10.1016/j.biocel.2022.106191.

New Approaches and Biomarker Candidates for the Early Detection of Ovarian Cancer.

Hossain K, Escobar Bermeo J, Warton K, Valenzuela S Front Bioeng Biotechnol. 2022; 10:819183.

PMID: 35223789 PMC: 8867026. DOI: 10.3389/fbioe.2022.819183.

References

Hong L, Yang Z, Ma J, Fan D . Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets. 2013; 14(10):1118-27. DOI: 10.2174/13894501113149990183. View

Mitamura T, Watari H, Wang L, Kanno H, Hassan M, Miyazaki M . Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis. 2013; 2:e40. PMC: 3641356. DOI: 10.1038/oncsis.2013.3. View

Merritt W, Lin Y, Han L, Kamat A, Spannuth W, Schmandt R . Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008; 359(25):2641-50. PMC: 2710981. DOI: 10.1056/NEJMoa0803785. View

Iorio M, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P . MicroRNA signatures in human ovarian cancer. Cancer Res. 2007; 67(18):8699-707. DOI: 10.1158/0008-5472.CAN-07-1936. View

Minegishi T, Kameda T, Hirakawa T, Abe K, Tano M, Ibuki Y . Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms. Clin Cancer Res. 2000; 6(7):2764-70. View

Yasuda K, Torigoe T, Morita R, Kuroda T, Takahashi A, Matsuzaki J . Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. PLoS One. 2013; 8(8):e68187. PMC: 3742724. DOI: 10.1371/journal.pone.0068187. View

Liu J, Xiao Z, Wong S, Tin V, Ho K, Wang J . Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells. Oncotarget. 2013; 4(10):1698-1711. PMC: 3858556. DOI: 10.18632/oncotarget.1246. View

Wyman S, Parkin R, Mitchell P, Fritz B, OBriant K, Godwin A . Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One. 2009; 4(4):e5311. PMC: 2668797. DOI: 10.1371/journal.pone.0005311. View

Heintz A, Odicino F, Maisonneuve P, Quinn M, Benedet J, Creasman W . Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S161-92. DOI: 10.1016/S0020-7292(06)60033-7. View

10.

Nagaraja A, Creighton C, Yu Z, Zhu H, Gunaratne P, Reid J . A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010; 24(2):447-63. PMC: 2817607. DOI: 10.1210/me.2009-0295. View

11.

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

12.

Weiderpass E, Sandin S, Inoue M, Shimazu T, Iwasaki M, Sasazuki S . Risk factors for epithelial ovarian cancer in Japan - results from the Japan Public Health Center-based Prospective Study cohort. Int J Oncol. 2011; 40(1):21-30. DOI: 10.3892/ijo.2011.1194. View

13.

Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C . A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 2010; 116(17):4043-53. PMC: 2930033. DOI: 10.1002/cncr.25204. View

14.

Peng D, Luo M, Qiu L, He Y, Wang X . Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012; 27(4):1238-44. PMC: 3583406. DOI: 10.3892/or.2012.1625. View

15.

Voorhoeve P, le Sage C, Schrier M, Gillis A, Stoop H, Nagel R . A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006; 124(6):1169-81. DOI: 10.1016/j.cell.2006.02.037. View

16.

Nam E, Yoon H, Kim S, Kim H, Kim Y, Kim J . MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008; 14(9):2690-5. DOI: 10.1158/1078-0432.CCR-07-1731. View

17.

Mase Y, Ishibashi O, Ishikawa T, Takizawa T, Kiguchi K, Ohba T . MiR-21 is enriched in the RNA-induced silencing complex and targets COL4A1 in human granulosa cell lines. Reprod Sci. 2012; 19(10):1030-40. DOI: 10.1177/1933719112442245. View

18.

Andrade A, Borges K, Castro-Gamero A, Silveira V, Suazo V, Oliveira J . Zebularine induces chemosensitization to methotrexate and efficiently decreases AhR gene methylation in childhood acute lymphoblastic leukemia cells. Anticancer Drugs. 2013; 25(1):72-81. DOI: 10.1097/CAD.0000000000000028. View

19.

Dai F, Zhang Y, Zhu X, Shan N, Chen Y . Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation. Target Oncol. 2012; 7(4):217-25. DOI: 10.1007/s11523-012-0236-7. View

20.

Li B, Cheng X, Yang Y, Li Z . GRP78 mediates radiation resistance of a stem cell-like subpopulation within the MCF-7 breast cancer cell line. Oncol Rep. 2013; 30(5):2119-26. DOI: 10.3892/or.2013.2710. View